Add like
Add dislike
Add to saved papers

Rectal sleeve advancement for the treatment of persistent rectovaginal fistulas.

BACKGROUND: Different surgical procedures are available for rectovaginal fistula repair. Most of these procedures fail in a substantial number of women, especially in those with a persistent fistula after prior attempts at repair. In addition, these procedures have a potential risk of dyspareunia and impairment of continence. The question is whether rectal sleeve advancement could be a valuable option for women with such a persistent rectovaginal fistula. The present study was aimed to examine the feasibility of this new procedure.

PATIENTS AND METHODS: Eight consecutive women (median age 41 years; range 28-53) with a persistent, low rectovaginal fistula underwent rectal sleeve advancement, six patients by a posterior "Kraske" approach and two patients by an abdominal approach. The aetiologies were obstetric trauma (n = 4), prior anal surgery (n = 2) and cryptoglandular fistulous disease (n = 2).

RESULTS: Five patients had an uneventful postoperative course. Three patients encountered recurrent symptoms shortly after the procedure. In these three patients an additional transanal approach was performed to close the anal opening of the fistulous tract. This additional approach was successful in one patient. The median duration of follow-up was 12 months (range 3-17). The overall healing rate was 75%. None of the patients encountered de novo dyspareunia. One patient encountered involuntary loss of stool during the night postoperatively.

CONCLUSION: Based on these early results, rectal sleeve advancement, either by a posterior "Kraske" approach, or by an abdominal approach, seems to be a valuable alternative for the treatment of persistent rectovaginal fistulas.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app